Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2022 - 03 - 01 save search
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Published: 2022-03-01 (Crawled : 19:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.8%
H: 1.31%
C: 0.75%
il-12 program therapeutics immunotherapy one phase 1 therapy phase 2 milestone
J&J, Legend Introduce New CAR-T Therapy to Multiple Myeloma Market
Published: 2022-03-01 (Crawled : 15:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
car-t therapy
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
ITCI | News 0 d | $72.29 0.4% 0.4% 2.2M
|
Health Technology
|
| O: -0.87%
H: 7.05%
C: 2.73%
financial results cel report results therapy
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
| O: -1.87%
H: 4.76%
C: 4.29%
health heart trial cel therapy cardiamp
MT Cap for NeuroStar Advanced Therapy for Mental Health Now Available Nationwide
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: -0.59%
H: 0.6%
C: -2.08%
health star neurostar therapy
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Published: 2022-03-01 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
phase 2 trial therapeutics therapy cancer pancreatic enroll
With Market Size Valued at $6.6 Billion by 2026, it`s a Healthy Outlook for the Global Radiation Therapy Equipment Market
Published: 2022-03-01 (Crawled : 13:00) - prnewswire.com
ARAY | $2.135 -3.39% -3.51% 630K
|
Health Technology
|
| O: -2.97%
H: 2.92%
C: -0.58%
health radiation therapy therapy
Long term study confirms efficacy of ISA Pharmaceuticals' T-cell activating immunotherapy in combination with checkpoint inhibitor
Published: 2022-03-01 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
als long term cel immunotherapy therapy t-cell
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 09:00) - biospace.com/
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.26%
treatment fda fda approval car-t approval cel therapy
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
treatment fda car-t cel immunotherapy therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.